Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cabergoline · 1 trial · 2 indications
Overall Response Rate (ORR) is defined as the number of patients that achieved Complete Response (CR) or Partial Response (PR) and will be assessed after 8 weeks (2 cycles) of therapy using CT scan images and RECIST guidelines. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LD. Progressive Disease (PD): At least a 20% increase in the sum o the LD of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of LD since the treatment started
| Arm | Type | Description |
|---|---|---|
| Treatment (cabergoline) | EXPERIMENTAL | Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| cabergoline | DRUG | Given orally |
Inclusion Criteria: * Patients must have histologically confirmed metastatic breast cancer; tissue (a minimum of 3 slides) from the most recent biopsy is required for review and confirmation of eligibility; NOTE: material should ideally be from the metastatic disease, however material from the prim...
Top 20 of 94 competitors
Cabergoline is being studied as a treatment for recurrent breast cancer, specifically in patients with stage IV breast cancer. It is an investigational small molecule in Phase 1 clinical development for this oncology indication. The drug has been evaluated in a completed early Phase 1 trial in the United States.
Cabergoline is a small molecule being developed for recurrent breast cancer. The specific molecular target for this indication has not been disclosed in the available clinical trial information. The drug is being studied in a Phase 1 trial for patients with stage IV breast cancer.
Sage Therapeutics, Inc. (NASDAQ: SAGE) is the developer of cabergoline for recurrent breast cancer. The company is conducting clinical research on this small molecule in the oncology therapeutic area, with a completed early Phase 1 trial in metastatic breast cancer.
Cabergoline is in Phase 1 clinical development for recurrent breast cancer. A completed early Phase 1 trial (NCT01730729) evaluated the drug in 20 female patients with stage IV breast cancer. The drug remains investigational and is not approved for this indication.
Cabergoline has been studied in one clinical trial, NCT01730729, titled "Cabergoline in Metastatic Breast Cancer." This early Phase 1 trial was completed in the United States and enrolled 20 female patients aged 18 years and older with recurrent or stage IV breast cancer. The trial was uncontrolled and not randomized.
Cabergoline is a distinct small molecule being investigated for recurrent breast cancer. No alternative names for this drug have been reported in the clinical trial data. It is being studied as a monotherapy in an uncontrolled early Phase 1 trial for metastatic breast cancer.